Teladoc Health Inc (NYSE:TDOC) President Peter A. Mcclennen sold 69,224 shares of the stock in a transaction that occurred on Monday, November 5th. The shares were sold at an average price of $66.77, for a total transaction of $4,622,086.48. Following the transaction, the president now owns 12,692 shares in the company, valued at approximately $847,444.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NYSE TDOC traded up $4.77 during midday trading on Wednesday, reaching $68.18. The stock had a trading volume of 139,537 shares, compared to its average volume of 2,099,172. The company has a debt-to-equity ratio of 0.40, a current ratio of 8.99 and a quick ratio of 8.99. The stock has a market cap of $5.04 billion, a PE ratio of -41.28 and a beta of 0.96. Teladoc Health Inc has a 12-month low of $27.30 and a 12-month high of $89.05.
Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Thursday, November 1st. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.02. The firm had revenue of $111.00 million during the quarter, compared to analysts’ expectations of $109.94 million. Teladoc Health had a negative net margin of 31.32% and a negative return on equity of 14.05%. The company’s revenue for the quarter was up 61.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.55) earnings per share. On average, research analysts expect that Teladoc Health Inc will post -1.46 EPS for the current year.
A number of research analysts recently weighed in on TDOC shares. Jefferies Financial Group set a $74.00 price objective on shares of Teladoc Health and gave the company a “buy” rating in a research report on Wednesday, July 11th. Citigroup increased their price target on shares of Teladoc Health to $80.00 and gave the stock a “buy” rating in a research report on Thursday, July 19th. Canaccord Genuity reiterated a “buy” rating and issued a $70.00 price target (up from $63.00) on shares of Teladoc Health in a research report on Wednesday, July 25th. Robert W. Baird increased their price target on shares of Teladoc Health from $50.00 to $65.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 25th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $52.00 price target on shares of Teladoc Health in a research report on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $82.95.
COPYRIGHT VIOLATION WARNING: This piece was reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.wkrb13.com/2018/11/07/insider-selling-teladoc-health-inc-tdoc-president-sells-69224-shares-of-stock.html.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Featured Article: Diversification Important in Investing
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.